TF and myeloproliferative neoplasm: Consistently, Taniguchi et al. described that plasma levels of procoagulant EVs expressing TF were significantly higher in MPN patients (mostly including PV and ET) suffering thrombotic events than in patients without such events, suggesting that TF-positive EVs may be considered a biomarker of thrombosis.